|
Indian Journal of Pharmacology, Vol. 37, No. 3, May-June, 2005, pp. 169-173 Research Paper Effect of sodium sulfadimethylpyrimidine on multiple forms of cytochrome P450 in chicken Adav SS, Padmawar PA, Govindwar SP Department of Biochemistry, Shivaji University, Kolhapur Code Number: ph05042 Abstract OBJECTIVE: To study the effect of sodium sulfadimethylpyrimidine (SDMP) on different forms of CYP 450 enzymes induced by phenobarbital (CYP 2B1, 2B2 and 3A), isoniazid (CYP 2E1), benzo(a)pyrene (CYP 1A1), clotrimazole (CYP 3A), and clofibrate (CYP 4A).MATERIALS AND METHODS: Chickens (Hubbard, male) weighing 250-300 g were divided into 17 groups of six each. Five experimental sets were prepared containing three subgroups each to test five different inducers. Microsomes were isolated by calcium precipitation. The levels of electron transport components, CYP 450, cytochrome b5, and cytochrome c-reductase were determined using extinction coefficients. Activities of drug-metabolizing enzymes were assayed. RESULTS: All inducers (phenobarbital, isoniazid, benzo(a)pyrene, clotrimazole, and clofibrate) showed significant induction of mixed function oxidase in chicken. The SDMP treatment of inducer-pretreated chicken caused a significant decrease in electron transport components and activities of drug-metabolizing enzymes when compared with treatment of inducer alone. Phenobarbital, isoniazid, and benzo(a)pyrene treatments of SDMP-pretreated chicken showed no significant change in induction pattern, however, significant alterations were observed in the induction pattern of clotrimazole and clofibrate. CONCLUSION : Our studies suggest that CYP 2B1, 2B2, 3A; CYP 2E1; CYP 1A1; CYP 3A and CYP 4A are susceptible species of CYP 450 to SDMP and its metabolites. The SDMP also affected in the induction pattern of some of the inducers with respect to CYP 450 isoforms. Keywords: Aniline hydroxylase; aminopyrine N -demethylase; CYP 450; mixed function oxidase; sodium; sulfadimethylpyrimidine Introduction Microsomal cytochrome P450 (CYP 450) consists of a multigene family that plays an important role in the metabolism of a wide variety of endogenous compounds and xenobiotics including drugs, carcinogens, toxic chemicals, steroids, and fatty acids.[1] These liver microsomal CYP 450 isozymes exhibit broad, often overlapping specificities towards their substrates and are differentially regulated by several factors including sex, age, and administration of drugs.[2],[3],[4],[5],[6] Depending on the isozymes and substrate, different forms of CYP 450 may catalyze the metabolism of a particular substrate at comparable rates but biotransform other substrates at significantly different rates. Rat CYP 450 b and rabbit LM2 catalyze the N -demethylation of benzphetamine 100 times faster than other enzymes.[5] Rat liver CYP 450 a, 450 b, and 450 c preferentially hydrolyze testosterone at the 7α, 17 α, and 6 β positions, respectively. The available evidence indicates that the presence of different CYP 450 isozymes in tissues from various sources is primarily responsible for the observed differences in metabolism. The difference in substrate specificity, regiospecificity, and stereospecificity of various CYP 450 isozymes plays an important role in regulation pathways of a given drug. Thus, the relative proportions of various forms of CYP 450 in a given tissue or individual is an important factor in determining the cytotoxic and carcinogenic action of many toxic compounds. Sodium sulfadimethylpyrimidine (SDMP) is routinely used for acute coccidiosis, coryza, cholera, pullorum, and antipestifer diseases in chicken.[7] The SDMP influences mixed function oxidase in chicken and it depends on the dose, duration of SDMP treatment and strain of chicken.[8] The SDMP (300 mg/kg, body weight) treatment to chicken decreases the levels of electron transport components and drug-metabolizing enzymes. In vitro addition of SDMP shows the inhibitory action on CYP 450.[8] However, the effect of SDMP on various forms of CYP 450 is still unknown, hence the present work was undertaken to study the effect of SDMP on different forms of CYP 450 enzymes.Materials and methods Animals Chemicals Treatment of animals Preparation of microsomes Microsomal enzyme assays
Statistical analysis Results Administration of SDMP showed significant decrease in electron transport components and drug-metabolizing enzymes as observed earlier.[9] Phenobarbital, isoniazid, benzo(a)pyrene treatments showed significant induction of microsomal protein, however, treatment with clotrimazole and clofibrate did not show any significant change. Significant increases were observed in electron transport components and drug-metabolizing enzymes due to phenobarbital, isoniazid, benzo(a)pyrene, clotrimazole, and clofibrate, except cytochrome c-reductase in benzo(a)pyrene treatment [Table - 1] and [Table - 2]. The SDPM treatment of phenobarbital, isoniazid, clotrimazole or clofibrate pretreated chicken did not change the level of microsomal proteins except in benzo(a)pyrene, when compared with respective control. However, significant decrease in CYP 450, cytochrome b5, cytochrome c-reductase, aminopyrine N -demethylase, and aniline hydroxylase was observed when compared with the respective control groups [Table - 1] and [Table - 2]. Inducer (phenobarbital, benzo(a)pyrene or clotrimazole) treatment of SDMP pretreated chicken showed no significant change in electron transport components and drug-metabolizing enzymes when compared with respective control (inducer treatment alone), except, SDMP treatment prior to clotrimazole resulted in a significant increase in the activities of cytochrome c-reductase and aniline hydroxylase, when compared to clotrimazole alone. Isoniazid treatment of SDMP pretreated chicken caused significant decrease in microsomal protein, CYP 450, cytochrome b5, and aminopyrine N -demethylase when compared to isoniazid treatment alone. Clofibrate treatment after SDMP pretreatment also resulted in noticeable increase in cytochrome b5, CYP 450, and aniline hydroxylase when compared with control. A significant decrease in cytochrome b5, CYP 450, and cytochrome c-reductase was observed due to clofibrate treatment of SDMP pretreated chicken when compared with clofibrate treatment alone [Table - 1] and [Table - 2]. A significant inhibition (of 21-61% and 13-27%) of aminopyrine N -demethylase, and aniline hydroxylase activities was observed due to in vitro addition of SDMP (4.2 mM) in SDMP, phenobarbital, benzo(a)pyrene, isoniazid, clotrimazole, and clofibrate-treated chicken liver microsomes (data not shown). Discussion The SDMP is used as a marker of N -acetylation in man for genetic determination of the N -acetyl transferase activity.[16],[17],[18] Other than acetylation, these drugs can be metabolized by glucuronidation, sulfation, and oxidation to hydroxylamine, which depends on species and physiological conditions.[19],[20] Our earlier investigation showed biphasic response of SDMP, inhibition of catalytic and spectral activity of CYP 450 due to addition of SDMP in vitro .[8] No alteration in phenobarbital sleeping time in SDMP-treated rats and differential induction pattern in different strains of chicken[8] encouraged us to study the effect of SDMP on various CYP 450 isoforms. The main objective was to study the effect on phenobarbital induced CYP 2B1, 2B2, 3A; isoniazid induced CYP 2E1; benzo(a)pyrene induced CYP 1A1; Clotrimazole induced CYP 3A and clofibrate induced CYP 4A microsomal CYP 450. The protein levels and other parameters of mixed function oxidase system were increased following phenobarbital treatment. The CYP 2B3 is not induced by phenobarbital, whereas CYP 450 2B1, 2B2 are phenobarbital inducible. Indeed, it seems the phenobarbital induction is not limited to CYP 450, in so far as several other enzymes that contribute to foreign compound metabolism including aldehyde dehydrogenase, epoxide hydroxylase, NADPH-cytochrome P450 reductase, UDP-glucuronosyl transferase and several glutathione s-transferase are inducible by Phenobarbital.[21],[22],[23] The effect of phenobarbital, unlike those 3-methylcholanthrene, include proliferation of smooth endoplasmic reticulum, stimulation of liver weight gain, liver tumor promotion, and general stabilization of liver microsomal protein and are thus pleiotropic.[24] No alteration in the levels of CYP 450 and drug-metabolizing enzymes due to pretreatment of SDMP indicates any significant effect of SDMP or it′s metabolites on the induction mechanism of phenobarbital. Hence there is no alteration in phenobarbital sleeping time in chicken. Isoniazid was found to be a strong inducer of mixed function oxidase system. Benzo(a)pyrene treatment of chickens showed a significant increase in microsomal proteins, electron transport components and drug-metabolizing enzymes which is usually observed in rats.[25] The SDMP treatment of benzo(a)pyrene pretreated chickens showed significant decrease in the electron transport components and drug-metabolizing enzymes which indicates susceptibility of CYP 1A1 to SDMP. Benzo(a)pyrene treatment of SDMP pretreated chicken showed no change in CYP 450, cytochrome c-reductase, and the activity of aniline hydroxylase when compared with benzo(a)pyrene treatment alone. However, a significant decrease in aminopyrine N -demethylase may be because of partial destruction of CYP 450 due to residual SDMP or it′s metabolites. Clotrimazole is a specific inducer of CYP 3A activity.[26] Post-treatment of SDMP to clotrimazole pretreated chicken showed a significant decrease in electron transport components and drug-metabolizing enzymes. This indicates that CYP 3A is sensitive to SDMP and it′s metabolites. As can be seen from the prior treatment of SDMP to clotriamazole-treated chicken, further increase in the activities of cytochrome c-reductase, and aniline hydroxylase indicates the enhancement of inductive mechanism. A unique induction pattern from clofibrate treatment has been observed previously.[27] To observe the effect of SDMP or it′s metabolites on CYP 4A activity, the chicken were injected with a well-known inducer clofibrate. Clofibrate treatment to male chicken showed significant increase in the electron transport components and drug-metabolizing enzymes. Clofibrate treatment prior to SDMP treatment resulted in significant decrease in the levels of electron transport components and drug-metabolizing enzymes compared with clofibrate treatment alone. This indicates the destruction of CYP 4A is due to SDMP or it is metabolites. It is surprising to note significant low levels of electron transport components with insignificant changes in the activities of drug-metabolizing enzymes due to post-treatment of clofibrate to SDMP-treated chicken when compared with the clofibrate treatment alone. It clearly indicates that the alteration in the inductive mechanism of clofibrate. In vitro addition of SDMP (4.2 mM) in microsomal incubates obtained from various inducer treatments showed different percent inhibition in aminopyrine N -demethylase, and aniline hydroxylase activity. It is also reported that of aminopyrine N -demethylase is inhibited more than aniline hydroxylase activity, which indicate that the inhibition is depending on the composition of isozymes of CYP 450. With consideration of overlapping substrate specificity and multiplicity of CYP 450, it can be concluded that CYP 2E1 might be a resistant species. The CYP 2B1, CYP 2B2, 3A, and CYP 1A1 forms were found to be more susceptible. In conclusion, this investigation indicates that all inducers viz., phenobarbital, isoniazid, benzo(a)pyrene, clotrimazole, and clofibrate of mixed function oxidase in rodents also show induction in avian system. Significant decrease in electron transport components and levels of drug-metabolizing enzymes due to SDMP post-treatment indicates the susceptibility of CYP 2B1, CYP 2B2, 3A; CYP 2E1; CYP 1A1; CYP 3A and CYP 4A to SDMP or it′s metabolites. The SDMP does not have significant effect on induction pattern of phenobarbital, isoniazid, and benzo(a)pyrene. However, it certainly modulates the induction pattern with respect to isoforms of CYP 450 in case of clotrimazole, and clofibrate. References
Copyright 2005 - Indian Journal of Pharmacology The following images related to this document are available:Photo images[ph05042t1.jpg] [ph05042t2.jpg] |
|